MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,773.95
+0.66%
NASDAQ 100
$31,076.44
+0.87%
DOW JONES
$51,268.00
+0.18%
NASDAQ Composite
$27,477.31
+1.05%
RUSSELL 2000
$2,833.80
+0.66%
CBOE VIX
$15.52
+1.37%
Sector Heatmap
Technology+0.56%
Financials+0.73%
Healthcare+0.72%
Consumer Cycl+0.35%
Consumer Staples+0.63%
Energy+0.99%
Industrials+0.09%
Materials+1.31%
Real Estate-0.34%
Utilities+0.35%
Comm Services+1.17%
IMA — ImageneBio, Inc. Common Stock
NasdaqImageneBio, Inc. Common Stock
$4.70
+0.10(+2.17%)
- O
- 4.60
- H
- 4.73
- L
- 4.60
- V
- 8.53K
⏱️ End-of-day dataAs of Oct 5, 2026
Chart
About IMA
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SectorNot available
IPO DateJul 28, 2025
Employees18
Stock ExchangeNasdaq
Ticker SymbolIMA
Websitehttps://www.imagenebio.com
Key Financial Statistics
| Market Cap | $52.22M |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $3.94 - $9.10 |
| 52-Week Avg Volume | 114.6K |
| VWAP | $4.69 |
| Transactions | 123 |
| Total Recorded Bars | 1,388 days |